With Sprout Pharmaceuticals winning approval for its new drug, Addyi, earlier this week, we decided to check TheStreet Quant Ratings for stocks in the health care industry to invest in. We narrowed it down to large-cap managed health care stocks. Addyi is the first drug that helps women’s sex drive. It is dubbed as ‘women’s Viagra.’ It is expected to be popular — so popular that Valeant Pharmaceuticals announced it will acquire Sprout Pharmaceuticals for $1 billion. Valeant is rated as a ‘buy,’ by our stock-rating algorithm, TheStreet Ratings. Here are some of the best managed health care stocks our algorithm says you should consider looking at. Number 3 is Aetna. With an ‘A’ rating, the company’s strengths can be seen in its revenue growth and increase in net income. 2nd is, Anthem. This rating is an ‘A+.’ Anthem thrives in its solid stock price performance and revenue growth. Number 1 is UnitedHealth Group. This is also an ‘A+.’ The company flourishes in its revenue growth and notable return on equity. TheStreet Ratings are algorithmic stock picks based on 32 major data points. S&P 500 stocks rated ‘buy’ yielded a 16-and-a-half-percent return in 2014, beating the S&P 500 Total Return Index by more than 300 basis points. For the full reports on these stocks, you can check out TheStreet.com/QuantRatings.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
